Literature DB >> 2569990

Proliferation antigens in cutaneous melanocytic tumors--an immunohistochemical study comparing the transferrin receptor and the Ki 67 antigen.

H P Soyer1, J Smolle, F M Smolle-Juettner, H Kerl.   

Abstract

The cellular reactivities with the monoclonal antibodies OKT9 and Ki 67 have been demonstrated to be closely related to proliferation in various malignant neoplasms. In this study a total of 25 melanocytic skin tumors was examined immunohistochemically with both antibodies and the results were evaluated semiquantitatively for OKT9 and quantitatively for Ki 67 by stereological methods. All cases of primary and metastatic malignant melanoma expressed a strong stainability for OKT9, whereas benign melanocytic nevi were almost completely negative. Our results with the monoclonal antibody Ki 67 revealed highly significant differences in the numerical density of Ki-67-positive cells between metastatic malignant melanoma (number of positive cells: 47.0 +/- 9.2 X 10(3)/mm3), primary malignant melanoma (6.3 +/- 1.9 X 10(3)/mm3) and benign melanocytic nevi (2.2 +/- 0.7 X 10(3)/mm3). Correlation analysis between mean percentage of OKT9-positive cells and numerical density of Ki-67-positive cells revealed a significant correlation of both parameters (r = 0.58; p less than or equal to 0.05), indicating a positive relationship of OKT9 and Ki 67 expression. Especially in primary malignant melanoma, however, the amount of OKT9-positive cells considerably exceeds that of Ki-67-positive cells. The monoclonal antibodies OKT9 and Ki 67 reflect 'proliferative activity' in melanocytic skin tumors, as both are expressed in significantly higher amounts in primary and metastatic malignant melanomas. The combined application of these antibodies in cutaneous melanocytic lesions might be of diagnostic and prognostic value.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569990     DOI: 10.1159/000248090

Source DB:  PubMed          Journal:  Dermatologica        ISSN: 0011-9075


  9 in total

1.  mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation.

Authors:  William Damsky; Goran Micevic; Katrina Meeth; Viswanathan Muthusamy; David P Curley; Manjula Santhanakrishnan; Ildiko Erdelyi; James T Platt; Laura Huang; Nicholas Theodosakis; M Raza Zaidi; Scott Tighe; Michael A Davies; David Dankort; Martin McMahon; Glenn Merlino; Nabeel Bardeesy; Marcus Bosenberg
Journal:  Cancer Cell       Date:  2015-01-12       Impact factor: 31.743

Review 2.  Melanocytic nevi and melanoma: unraveling a complex relationship.

Authors:  W E Damsky; M Bosenberg
Journal:  Oncogene       Date:  2017-06-12       Impact factor: 9.867

Review 3.  Etiopathogenesis of cholesteatoma.

Authors:  Ewa Olszewska; Mathias Wagner; Manuel Bernal-Sprekelsen; Jörg Ebmeyer; Stefan Dazert; Henning Hildmann; Holger Sudhoff
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-06-27       Impact factor: 2.503

4.  Immunohistochemical localization of proliferating cell nuclear antigen/cyclin in human skin.

Authors:  F Furukawa; S Imamura; M Fujita; K Kinoshita; K Yoshitake; W R Brown; D A Norris
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

Review 5.  From melanocytes to melanomas.

Authors:  A Hunter Shain; Boris C Bastian
Journal:  Nat Rev Cancer       Date:  2016-04-29       Impact factor: 60.716

6.  Bcl-2 expression in human melanocytes and melanocytic tumors.

Authors:  J J van den Oord; N Vandeghinste; M De Ley; C De Wolf-Peeters
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

7.  Ki-67 antigen expression and growth pattern of basal cell carcinomas.

Authors:  H P Baum; I Meurer; G Unteregger
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

8.  An application of MIB antibody to the retrospective study of melanomas of oral mucosa and facial skin.

Authors:  M Korabiowska; U Brinck; J F Hoenig; S B Bartkowski; J Mirecka; A Schauer
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

9.  Retrospective study of small pet tumors treated with Artemisia annua and iron.

Authors:  Mohamed E M Saeed; Elmar Breuer; Mohamed-Elamir F Hegazy; Thomas Efferth
Journal:  Int J Oncol       Date:  2019-11-25       Impact factor: 5.650

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.